共 196 条
[1]
Stresing V(2007)Bisphosphonates in cancer therapy Cancer Lett 257 16-35
[2]
Daubine F(1999)Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344-1352
[3]
Benzaid I(2000)Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 4118-4124
[4]
Monkkonen H(2003)The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 349 1216-1226
[5]
Clezardin P(2001)Risk of new vertebral fracture in the year following a fracture JAMA 285 320-323
[6]
Harris ST(2000)BMD changes explains only a fraction of the observed fracture risk reduction in risedronate-treated patients Osteoporos Int 11 S203-259
[7]
Watts NB(1996)Prediction of fracture risk. I: Bone density Am J Med Sci 312 257-2123
[8]
Genant HK(2004)Structure and mechanical quality of the collagen-mineral nano-composite in bone J Mater Chem 14 2115-466
[9]
McKeever CD(2008)Bone mineralization density distribution in health and disease Bone 42 456-1300
[10]
Hangartner T(2004)Bone safety of long-term bisphosphonate treatment Curr Med Res Opin 20 1291-191